Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 4/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | CASP1 | P29466 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15094159 | 0.93 | PTGS1 (0.51) | PTGS1PTGS2MEN1KMT2AGAA | |
| SCHEMBL8215472 | 0.93 | PTGS1 (0.51) | PTGS1PTGS2MEN1KMT2AGAA | |
| SCHEMBL9291270 | 0.93 | PTGS1 (0.51) | PTGS1PTGS2MEN1KMT2AGAA | |
| Succinimide SCHEMBL28223747 | 0.90 | MEN1 (0.36) | PTGS1PTGS2MEN1KMT2AGAA | |
| SCHEMBL3902971 | 0.89 | MAPK1 (0.47) | MEN1KMT2AGAAMAPK1CYP1A2 | |
| SCHEMBL3877414 | 0.85 | CYP19A1 (0.41) | MEN1KMT2AGAAMAPK1SMN1; SMN2 | |
| SCHEMBL1325053 | 0.83 | CYP19A1 (0.42) | MEN1KMT2AGAAMAPK1SMN1; SMN2 | |
| SCHEMBL22571074 | 0.79 | CYP19A1 (0.51) | PTGS1PTGS2MEN1KMT2AGAA | |
| SCHEMBL22571073 | 0.79 | CYP19A1 (0.51) | PTGS1PTGS2MEN1KMT2AGAA | |
| SCHEMBL5919521 | 0.78 | TSHR (0.49) | MEN1KMT2AGAASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2007501812-A | — | — | 2007-02-01 | — | — | JP | claimed |
| US-20060182714-A1 | Synthesis and application of new structural well defined branched polymers as conjugating agents for peptides | NOVO NORDISK A/S (DK) | 2006-08-17 | — | — | US | claimed |
| EP-1654004-A2 | SYNTHESIS AND APPLICATION OF NEW STRUCTURAL WELL DEFINED BRANCHED POLYMERS AS CONJUGATING AGENTS FOR PEPTIDES | NOVO NORDISK A/S (DK) | 2006-05-10 | — | — | EP | claimed |
| WO-2005014049-A2 | SYNTHESIS AND APPLICATION OF NEW STRUCTURAL WELL DEFINED BRANCHED POLYMERS AS CONJUGATING AGENTS FOR PEPTIDES | NOVO NORDISK A/S (DK) | 2005-02-17 | — | — | WO | claimed |
| CN-105573054-A | COMPOUND AND COLORED CURABLE RESIN COMPOSITION | SUMITOMO CHEMICAL CO | 2016-05-11 | — | — | CN | disclosed |
| CN-105315722-A | Salified dye and coloring curable resin composition | SUMITOMO CHEMICAL CO | 2016-02-10 | — | — | CN | disclosed |
| US-8053410-B2 | Pegylated factor VII glycoforms | NOVO NORDISK HEALTH CARE A/G (CH) | 2011-11-08 | — | — | US | disclosed |
| EP-1517710-B1 | PEGYLATED FACTOR VII GLYCOFORMS | NOVO NORDISK HEALTHCARE AG (CH) | 2011-03-30 | — | — | EP | disclosed |
| US-20090240028-A1 | Synthesis and Application of New Structural Well Defined Branched Polymers as Conjugating Agents for Peptides | NOVO NORDISK A/S (DK) | 2009-09-24 | — | — | US | disclosed |
| US-20090227504-A1 | Pegylated Factor VII Glycoforms | NOVO NORDISK A/S (DK) | 2009-09-10 | — | — | US | disclosed |
| US-20080039373-A1 | Pegylated Factor VII Glycoforms | NOVO NORDISK A/S (DK) | 2008-02-14 | — | — | US | disclosed |
| US-20060182714-A1 | Synthesis and application of new structural well defined branched polymers as conjugating agents for peptides | NOVO NORDISK A/S (DK) | 2006-08-17 | — | — | US | disclosed |
| EP-1654004-A2 | SYNTHESIS AND APPLICATION OF NEW STRUCTURAL WELL DEFINED BRANCHED POLYMERS AS CONJUGATING AGENTS FOR PEPTIDES | NOVO NORDISK A/S (DK) | 2006-05-10 | — | — | EP | disclosed |
| US-20050113565-A1 | Pegylated factor VII glycoforms | KLAUSEN NIELS K (DK) | 2005-05-26 | — | — | US | disclosed |
| EP-1517710-A1 | PEGYLATED FACTOR VII GLYCOFORMS | Novo Nordisk Health Care AG (CH) | 2005-03-30 | — | — | EP | disclosed |
| WO-2005014049-A2 | SYNTHESIS AND APPLICATION OF NEW STRUCTURAL WELL DEFINED BRANCHED POLYMERS AS CONJUGATING AGENTS FOR PEPTIDES | NOVO NORDISK A/S (DK) | 2005-02-17 | — | — | WO | disclosed |
| WO-2004000366-A1 | PEGYLATED FACTOR VII GLYCOFORMS | NOVO NORDISK HEALTH CARE AG (CH) | 2003-12-31 | — | — | WO | disclosed |
| US-6372813-B1 | CROSSLINKING POLYACRYLAMIDE HYDROGEL, JOINING BIOMOLECULES ON SUPPORTS | MOTOROLA | 2002-04-16 | — | — | US | disclosed |
| US-5354871-A | Pyrroline N-oxide derivatives | NATIONAL RESEARCH COUNCIL OF CANADA (CA) | 1994-10-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227504-A1 | Pegylated Factor VII Glycoforms | F7, F13B, F5 | PTGS1 4063/4885PTGS2 4142/4885MEN1 2340/4885 |
| US-20060182714-A1 | Synthesis and application of new structural well defined branched polymers as conjugating agents for peptides | VIP, PTMS, PDGFA | PTGS1 3587/4885PTGS2 3691/4885MEN1 1142/4885 |
| US-20090240028-A1 | Synthesis and Application of New Structural Well Defined Branched Polymers as Conjugating Agents for Peptides | VIP, PTMS, PDGFA | PTGS1 3587/4885PTGS2 3691/4885MEN1 1142/4885 |
| US-20050113565-A1 | Pegylated factor VII glycoforms | F7, F13B, F5 | PTGS1 4063/4885PTGS2 4142/4885MEN1 2340/4885 |
| US-20080039373-A1 | Pegylated Factor VII Glycoforms | F7, F13B, F5 | PTGS1 4063/4885PTGS2 4142/4885MEN1 2340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.